TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00066157
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal placebo patch, changed every 3 days, for 12 months
Study: NCT00066157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet daily for 12 months
Study: NCT00119184
Drug: spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: spinal anesthesia
Study: NCT00965458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
Study: NCT01780974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules
Study: NCT01580163
Drug: Traditional Chinese Medicine JITAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet，Each tablet weight 0.4g
Study: NCT00923572
Drug: EE30/DRSP (Yasmin, BAY86-5131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
Study: NCT02716415
Drug: Destin Maximum Strength 40% Zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment
Study: NCT00256997
Drug: Oral atypical Antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
Study: NCT03863080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of Placebo
Study: NCT00792467
Drug: ITF2357
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
Study: NCT00991458
Drug: Placebo (Vehicle for Cyclosporine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Study: NCT03471507
Drug: Bonipar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
Study: NCT03471507
Drug: Diclofenac sodium topical solution 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
Study: NCT00104286
Drug: Troxatyl™ (Cytotoxic Chemotherapeutic)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01699438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets q.d. for 8 weeks
Study: NCT02419001
Drug: Period 1 - Treatment Sequence AB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
Study: NCT02419001
Drug: Period 1 - Treatment Sequence AC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
Study: NCT00239330
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00433420
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00433420
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02393378
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate tablet
Study: NCT02393378
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid Tablet
Study: NCT00354978
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
Study: NCT02426021
Drug: MLN1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of MLN1202
Study: NCT02426021
Drug: MLN1202 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of MLN1202 placebo
Study: NCT02887677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
Study: NCT04130204
Drug: DYV700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary transdermal delivery platform
Study: NCT00071890
Drug: Interleukin 2
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
Study: NCT00071890
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART from week 0 to week 24
Study: NCT00071890
Drug: Treatment interruption
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART is interrupted from week 24 in both arms
Study: NCT04130204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle transdermal delivery platform
Study: NCT01955252
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).~Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.~Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.~For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months
Study: NCT00545454
Drug: SSR150106
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00545454
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04248426
Drug: ATI-2173 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-2173 Placebo is used as an inactive comparator to ATI-2173. It will be dosed as a capsule by mouth.
Study: NCT01949818
Drug: Yangzhengxiaoji capsule combined with CHOP regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
Study: NCT01949818
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
Study: NCT00750061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01403636
Drug: SAR245409
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule Route of administration: oral
Study: NCT03417245
Drug: factor concentrates
Approvals — FDA: no, EMA: no, PMDA: no
Description: by intravenous (IV) injection
Study: NCT03337477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).
Study: NCT03181932
Drug: Placebo inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
Study: NCT00744497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01744262
Drug: Total intravenous anesthesia
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5\~4 µg/mL and remifentanil effect site concentration 2\~5 ng/mL.
Study: NCT01744262
Drug: Inhalation Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction with intravenous propofol bolus of 1.5\~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5\~2.0 % and remifentanil effect site concentration 2\~5 ng/mL.
Study: NCT02183649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02035891
Drug: placebo 0.5mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
Study: NCT01110902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00370968
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03694886
Drug: Caffeine Anhydrous with small sucrose pill
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule
Study: NCT03694886
Drug: Caffeine Anhydrous with large sucrose pill
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule
Study: NCT00431106
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
Study: NCT00457951
Drug: ODSH
Normalized name: Octasulfated Disaccharide Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized, Blinded, ODSH Arm
Study: NCT03868657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01193244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of \<50 ng/dL.
Study: NCT05361005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT01462370
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg tablet given orally for one dose.
Study: NCT01462370
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.
Study: NCT01462370
Drug: Placebo to etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to etoricoxib, one tablet.
Study: NCT01462370
Drug: Placebo to ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to ibuprofen, up to four 3-capsule doses.
Study: NCT01462370
Drug: Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.
Study: NCT04435431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use
Study: NCT00003526
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT03877510
Drug: IPX203
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX203 extended release capsules
Study: NCT01038843
Drug: VA106483
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above
Study: NCT01747876
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEE011 is a small molecule inhibitor of CDK4/6.
Study: NCT00912431
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 administered on Day 1 of Period 1
Study: NCT00912431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for ABT-126 administered on Day 1 of Period 2
Study: NCT00988806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.
Study: NCT03023358
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m2 iv on day 1
Study: NCT03023358
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/m2 iv on day 1
Study: NCT00740649
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02870907
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m²/d, IV from D22 to D26.
Study: NCT02870907
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m²/d, IV from D22 à D24.
Study: NCT04617626
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of azithromycin suspension
Study: NCT02802540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients going to take capsules of placebo until complete 8 weeks.
Study: NCT00815659
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
Study: NCT03703427
Drug: Capecitabine, Oral, 500 Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250mg/m2，d1-d14，q3w
Study: NCT00639223
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 20mg capsule twice daily for 12 weeks
Study: NCT03894683
Drug: Melatonin 10 mg
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin tablets (10 mg)
Study: NCT03894683
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets manufactured the same as melatonin tablets
Study: NCT03071926
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg, qw, first 6 weeks ,every 8 weeks
Study: NCT03290131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT03075423
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care therapy is administered according to the physician´s decision.
Study: NCT00576433
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As prescribed
Study: NCT03920813
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.
Study: NCT02200406
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
Study: NCT02253446
Drug: Piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
Study: NCT02253446
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
Study: NCT00002696
Drug: CAF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002696
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002696
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002696
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002696
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002696
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01464437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01220817
Drug: 3 POMx capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 POMx capsules daily
Study: NCT00688012
Drug: SPC3649
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00818181
Drug: Biological: AL0206st
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03359590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment consists of placebo tablets for up to 24 weeks.
Study: NCT04047654
Drug: Non vitamin K oral anticoagulants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
Study: NCT01220817
Drug: 1 POMx capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 POMx capsule daily
Study: NCT02267343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01741727
Drug: ABT-414
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-414 will be administered by intravenous infusion.
Study: NCT03910244
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be given.
Study: NCT02636595
Drug: ABT-493/ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-493 coformulated with ABT-530
Study: NCT00072839
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo solution injected subcutaneously
Study: NCT00998296
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR inhibitor
Study: NCT00998296
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF inhibitor
Study: NCT00880919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
Study: NCT00982007
Drug: IV Iron (standard of care)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV standard of care (other IV iron) per the Investigator's discretion
Study: NCT03131375
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
Study: NCT02780180
Drug: QGC001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02780180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
Study: NCT01416987
Drug: Pergoveris®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received once daily injection of a single vial of Pergoveris® which contained 150 International Units (IU) of follitropin alfa (r-hFSH) and 75 IU of lutropin alfa (r-hLH), for approximately 8 days.
Study: NCT00814502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.